Andere talen Oncternal Therapeutics, Inc.

Aandelen

ONCT

US68236P2065

Vertraagde tijd Nasdaq Andere beurzen 17:58:26 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
8,682 ^USD	+5,23%		+5,23%	-19,04%

18/04	Oncternal kondigt aan dat de eerste patiënt is gedoseerd in het vierde cohort van de Fase 1/2-studie van ONCT-534 voor de behandeling van R/R-metastatische castratieresistente prostaatkanker	CI
15/04	ONCTERNAL THERAPEUTICS, INC. : HC Wainwright geeft koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	01/05
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	18/04
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	18/04
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer	15/03
Oncternal Therapeutics: Q4 Earnings Snapshot	07/03
Oncternal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results	07/03
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results	29/02
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	01/02
Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science	01/02
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	08/01
Oncternal Therapeutics, Inc. Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	08/01
Oncternal Therapeutics Announces Reverse Stock Split	04/01
Oncternal Therapeutics Reports Inducement Award under Nasdaq Listing Rule 5635(4)	03/01
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	02/01
Traders Look Ahead to Flat Day After Post-Christmas Rally	27/12
Top Premarket Decliners	27/12
Sector Update: Health Care Stocks Stronger Late Afternoon	26/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Oncternal Therapeutics, Inc.

Aandelen

ONCT

US68236P2065

Andere talen

Filters